Key result
Newly diagnosed T2DM linked to ~73% lower fasting plasma insulin compared to healthy controls.
Why the study?
The study aimed to compare insulin and C-peptide levels between patients with newly diagnosed T2DM and non-DM controls, and to evaluate their relationships with blood pressure, BMI, HOMA-IR, and HOMA-beta.
Do newly diagnosed, treatment-naive Type 2 diabetes mellitus patients have depleted fasting and stimulated plasma insulin and C-peptide levels compared to non-diabetic controls in Nigeria?
Case-Control (n=200)
No
Do newly diagnosed, treatment-naive Type 2 diabetes mellitus patients have depleted fasting and stimulated plasma insulin and C-peptide levels compared to non-diabetic controls in Nigeria?
Answers are grounded in this paper and cite their sources.
Newly diagnosed Nigerian T2DM patients exhibit severe pancreatic beta-cell secretory failure at diagnosis regardless of high obesity prevalence, supporting early C-peptide assessment to guide timely insulin initiation.
Objective: To compare insulin and C-peptide levels between patients with newly-diagnosed Type 2 diabetes mellitus (T2DM) and non-DM controls, and to assess relationships between insulin, C-peptide and blood pressure, body mass index (BMI) and the homeostatic model assessment (HOMA) of insulin resistance (HOMA-IR) and beta cell function (HOMA-β). Results: A case-control study of 100 newly-diagnosed, T2DM patients and 100 controls. Variables studied were fasting and 2-hour post-prandial (2HPP) glucose, insulin, C-peptide, HOMA-IR and HOMA-β. Compared to controls, cases had higher median BMI ( P < 0.001) and blood pressure ( P < 0.001), but lower plasma fasting insulin (FPI, 2.96 vs 10.87 µIU/ml; P = 0.001), 2HPP insulin (7.42 vs 13.21 µIU/Ml; P < 0.001), fasting C-peptide (0.17 vs 0.32 ng/ml; P < 0.001) and 2HPP C-peptide (0.60 vs 1.10 ng/ml; P < 0.001). Median FPI in cases was higher in men and correlated with HOMA-IR (Spearman ρ = 0.45; P < 0.001) and HOMA-β (Spearman ρ = 0.46; P < 0.001), but C-peptide didn’t differ by gender, BMI or glycemic control. These findings show newly diagnosed T2DM patients in the study area had depleted β-cell function. Early assessment of β-cell reserve among Nigerians with T2DM could guide early insulin therapy.
No takes yet. Share an insight, caveat, or question.
Abdullahi et al. (2026) conducted a case-control in Newly diagnosed Type 2 diabetes mellitus (n=200). Newly diagnosed Type 2 diabetes mellitus vs. Age- and sex-matched non-diabetic healthy controls was evaluated on Fasting plasma insulin (FPI, uIU/mL) (p=<0.001). Newly diagnosed T2DM patients had lower fasting plasma insulin and fasting C-peptide than non-diabetic controls.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: